Understanding Arrhythmia-induced Cardiomyopathy
Official title: Arrhythmia-induced Cardiomyopathy - a Prospective Observational Cohort Study
Run by University Hospital, Basel, Switzerland · NCT05662293 · Data updated 2026-11-12
This study is trying to learn more about how common arrhythmia-induced heart problems are in patients with weakened heart function and what factors might lead to worse outcomes or hospital visits.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2700 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | June 10, 2021 |
| Main results expected | January 2026 |
| Study ends | January 2027 |
| Registry record updated | March 4, 2025 |
| Trial ID | NCT05662293 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with a diagnosis or suspicion of arrhythmia-induced cardiomyopathy and reduced left ventricular ejection fraction.
✕Probably not a fit
Patients with acute health conditions, terminal illnesses, or those under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather clinical data on patients suspected of having arrhythmia-induced cardiomyopathy (AiCM) at the University Hospital Basel. It includes a retrospective analysis of 1200 patients to determine the incidence of AiCM in those with reduced left ventricular ejection fraction and a prospective cohort of 1500 patients to evaluate predictors of adverse events and re-hospitalizations. Diagnosis will be confirmed by two independent cardiologists using comprehensive clinical data. The study seeks to optimize patient care by establishing the prevalence of AiCM and improving diagnostic criteria.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management of arrhythmia-induced cardiomyopathy, improving patient outcomes.
How similar studies have gone: While the specific approach of this study is novel, previous studies have highlighted the importance of recognizing and diagnosing arrhythmia-induced cardiomyopathy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Prospective part Inclusion Criteria: * Diagnostic or suspicion of AiCM as presence of specified keyword in patient's file or as screened by colleagues of the internal medicine or cardiology clinics * Signed study consent Exclusion Criteria: * Patient's active refusal of the general consent of the University Hospital Basel * Age \<18 years old * Temporary exclusion criteria: Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (\>100 bpm, \<90 systolic BP, evidence of organ dysfunction). * Life expectancy \<1 year (palliative, terminal cancer) Retrospective part Inclusion Criteria: * Patients with a reduced left-ventricular ejection fraction (LVEF ≤50%) or a reduction of 15% in the ejection fraction (EF) between two echocardiographies and a concomitant diagnosis of any arrhythmia likely to lead to AiCM within one year before or after diagnosis of the reduced LVEF from 2010-2021 Exclusion Criteria: * Age \< 18 years old * Patient's active refusal of the general consent of the University Hospital Basel * Acute event clearly leading to an acutely reduced LVEF (massive type I myocardial infarction, cardiogenic shock from a coronary or myocardial etiology, septic shock leading to toxic myopathy, hypovolemic shock with reduced EF, cardiac arrest and/or need for resuscitation). * Patients with life expectancy \<1 year (palliative, terminal cancer)
Where it's running
-
University Hospital Basel, Department of Cardiology
Basel, Switzerland Recruiting
Study contacts
- Principal investigator: Patrick Badertscher, MD — University Hospital Basel, Department of Cardiology
- Study coordinator: Patrick Badertscher, MD
- Email: patrick.badertscher@usb.ch
- Phone: +41 61 556 58 23
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding the genetics of arrhythmia-induced cardiomyopathy
This study is trying to see if certain genetic traits in people with arrhythmia-induced cardiomyopathy can help predict their heart health and outcomes after treatment.
-
ATR 1072 in PRKAG2 Syndrome
A first-in-human study tests ATR 1072 to see if it is safe and how it behaves in adults with PRKAG2 Syndrome.
-
Modeling heart failure in Duchenne and Becker muscular dystrophy to find surrogate heart measures
This study will look at heart disease in people with Duchenne/Becker muscular dystrophy and carriers to see if MRI-based heart measures can predict death or major heart problems.
-
Multimodal Cardiac MRI to See How the Heart Is Working
This study tests a comprehensive MRI approach to characterize heart structure and tissue in adults with suspected or confirmed cardiovascular disease.
-
Genetic testing for AF-triggered cardiomyopathy
We will test whether people who develop heart failure during atrial fibrillation carry specific disease-causing gene variants compared with people who have AF but do not weaken their heart.
-
Mavacamten use and effectiveness in adults with obstructive hypertrophic cardiomyopathy in Japan
This project will see how well mavacamten works and how safe it is for adults in Japan with symptomatic obstructive hypertrophic cardiomyopathy who are receiving cibenzoline.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.